SANGEETA K. TYERECH, M.D.

PHILADELPHIA, PA

Research Active
Radiology - Radiation Oncology NPI registered 21+ years 1 publication 1996 – 1996 NPI: 1356347504
Radiology - Radiation Oncology Radiology - Radiation Oncology
RatsAdenocarcinomaTumor Cells, CulturedCell MovementActinsDose-Response Relationship, DrugChemotaxisMicrotubulesPseudopodiaCytochalasin DEpidermal Growth FactorMammary Neoplasms, ExperimentalNocodazole

Practice Location

333 COTTMAN AVE
PHILADELPHIA, PA 19111

Phone: (215) 728-6900

What does SANGEETA TYERECH research?

Dr. Tyerech studies the movement of cancer cells, with a particular emphasis on metastatic mammary adenocarcinoma, a type of breast cancer that has spread beyond its original location. Her research investigates how specific proteins, like EGF (Epidermal Growth Factor), influence the behavior of these aggressive cancer cells. By exploring the mechanisms of cell movement, she aims to identify potential targets for treatments that could prevent cancer from spreading in patients.

Key findings

  • EGF caused metastatic mammary adenocarcinoma cells (MTLn3) to rapidly extend lamellipods, a part of their structure, within just 5 minutes.
  • The most effective concentration of EGF in stimulating these extensions was 5 nanomolar (nM).
  • Understanding cell movement can contribute to developing strategies to inhibit the spread of metastatic breast cancer.

Frequently asked questions

Does Dr. Tyerech study breast cancer?
Yes, Dr. Tyerech specifically researches metastatic breast cancer and its cell movement.
What treatments has Dr. Tyerech researched?
While her work focuses on understanding cell movement, it contributes to finding new treatment methods to stop cancer spread.
Is Dr. Tyerech's work relevant to metastatic breast cancer patients?
Absolutely, her research is directly aimed at improving understanding and treatment options for patients with metastatic breast cancer.

Publications in plain English

EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism.

1996

Clinical & experimental metastasis

Segall JE, Tyerech S, Boselli L, Masseling S, Helft J +3 more

Plain English
This study looked at how a protein called EGF affects the movement of metastatic breast cancer cells (MTLn3 cells). They found that EGF caused these cells to extend part of their structure (called lamellipods) rapidly within 5 minutes, and the best results came from using 5 nanomolar (nM) EGF. Understanding these changes is important because it reveals how cancer cells move, which can help in developing treatments to stop their spread. Who this helps: This helps patients with metastatic breast cancer and their doctors in finding new treatment strategies.

PubMed

Frequent Co-Authors

J E Segall L Boselli S Masseling J Helft A Chan J Jones J Condeelis

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.